Endothelial growth factor receptor-mutant lung cancer and post-operative care management: one size does not fit all.
作者信息
Safi Javeryah, Gordon Sarah W, Lee Peter, Li Howard, Nana-Sinkam Patrick, Shah Rachit D, Shepherd Ray W, Shojaee Samira
机构信息
Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Virginia Commonwealth University, Richmond, VA, USA.
Department of Internal Medicine, Division of Hematology and Oncology, Virginia Commonwealth University, Richmond, VA, USA.
出版信息
Ann Transl Med. 2020 Dec;8(24):1697. doi: 10.21037/atm-20-4408.
Abstract
摘要
相似文献
1
Endothelial growth factor receptor-mutant lung cancer and post-operative care management: one size does not fit all.内皮生长因子受体突变型肺癌与术后护理管理：一刀切并不适用。
Ann Transl Med. 2020 Dec;8(24):1697. doi: 10.21037/atm-20-4408.
2
Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.双重抑制 Met 激酶和血管生成以克服 HGF 诱导的 EGFR 突变型肺癌中 EGFR-TKI 耐药性。
Am J Pathol. 2012 Sep;181(3):1034-43. doi: 10.1016/j.ajpath.2012.05.023. Epub 2012 Jul 9.
3
Diagnostic and Prognostic Performance of Serum Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor Receptor 2, and Osteopontin for Gastrointestinal Cancers.血清血管内皮生长因子、血管内皮生长因子受体2和骨桥蛋白对胃肠道癌症的诊断及预后价值
Clin Lab. 2019 Jan 1;65(1). doi: 10.7754/Clin.Lab.2018.180552.
4
Mutant epidermal growth factor receptor enhances induction of vascular endothelial growth factor by hypoxia and insulin-like growth factor-1 via a PI3 kinase dependent pathway.突变型表皮生长因子受体通过PI3激酶依赖性途径增强缺氧和胰岛素样生长因子-1对血管内皮生长因子的诱导作用。
Br J Cancer. 2001 May 18;84(10):1322-9. doi: 10.1054/bjoc.2001.1805.
5
Epidermal growth factor receptor mutation enhances expression of vascular endothelial growth factor in lung cancer.表皮生长因子受体突变增强肺癌中血管内皮生长因子的表达。
Oncol Lett. 2016 Dec;12(6):4598-4604. doi: 10.3892/ol.2016.5287. Epub 2016 Oct 18.
6
Vascular endothelial growth factor isoform and receptor expression during compensatory lung growth.血管内皮生长因子同工型和受体在代偿性肺生长过程中的表达。
J Surg Res. 2010 May 1;160(1):107-13. doi: 10.1016/j.jss.2008.10.007. Epub 2008 Dec 7.
7
Vascular endothelial growth factor and other biological predictors related to the postoperative survival rate on non-small cell lung cancer.血管内皮生长因子及其他与非小细胞肺癌术后生存率相关的生物学预测指标。
Lung Cancer. 2001 Aug-Sep;33(2-3):125-32. doi: 10.1016/s0169-5002(01)00195-7.
8
9
The K-ras gene regulates vascular endothelial growth factor gene expression in non-small cell lung cancers.K-ras基因调控非小细胞肺癌中血管内皮生长因子基因的表达。
Int J Oncol. 2000 Mar;16(3):501-11. doi: 10.3892/ijo.16.3.501.
10
Impact of serum vascular endothelial growth factor and interleukin-6 on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small-cell lung cancer.血清血管内皮生长因子和白细胞介素-6 对表皮生长因子受体酪氨酸激酶抑制剂治疗非小细胞肺癌患者的疗效影响。
Lung Cancer. 2018 Nov;125:22-28. doi: 10.1016/j.lungcan.2018.08.025. Epub 2018 Aug 31.
本文引用的文献
1
Annual report to the nation on the status of cancer, part II: Progress toward Healthy People 2020 objectives for 4 common cancers.国家癌症报告：第二部分——4 种常见癌症实现 2020 年健康目标的进展。
Cancer. 2020 May 15;126(10):2250-2266. doi: 10.1002/cncr.32801. Epub 2020 Mar 12.
2
Clinicopathological variables influencing overall survival, recurrence and post-recurrence survival in resected stage I non-small-cell lung cancer.影响Ⅰ期非小细胞肺癌切除术后总生存、复发和复发后生存的临床病理变量。
BMC Cancer. 2020 Feb 24;20(1):150. doi: 10.1186/s12885-020-6621-1.
3
Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition).转化医学学会关于表皮生长因子受体（EGFR）突变型肺癌术后管理的共识（2019年版）
Transl Lung Cancer Res. 2019 Dec;8(6):1163-1173. doi: 10.21037/tlcr.2019.12.14.
4
Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC.奥希替尼治疗未经治、-突变型晚期 NSCLC 的总生存期。
N Engl J Med. 2020 Jan 2;382(1):41-50. doi: 10.1056/NEJMoa1913662. Epub 2019 Nov 21.
5
SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.选择：表皮生长因子受体突变型非小细胞肺癌患者术后辅助厄洛替尼的 II 期临床试验。
J Clin Oncol. 2019 Jan 10;37(2):97-104. doi: 10.1200/JCO.18.00131. Epub 2018 Nov 16.
6
Local Cancer Recurrence: The Realities, Challenges, and Opportunities for New Therapies.局部癌症复发：新疗法的现实、挑战和机遇。
CA Cancer J Clin. 2018 Nov;68(6):488-505. doi: 10.3322/caac.21498. Epub 2018 Oct 17.
7
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018：GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
8
Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.厄洛替尼对比长春瑞滨联合顺铂用于表皮生长因子受体突变阳性的 IIIA 期非小细胞肺癌中国患者的辅助治疗（EVAN）：一项随机、开放标签、二期临床试验。
Lancet Respir Med. 2018 Nov;6(11):863-873. doi: 10.1016/S2213-2600(18)30277-7. Epub 2018 Aug 24.
9
Recent advances in the management of non-small cell lung cancer.非小细胞肺癌治疗的最新进展
F1000Res. 2017 Dec 7;6:2110. doi: 10.12688/f1000research.11471.1. eCollection 2017.
10
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.吉非替尼对比长春瑞滨联合顺铂作为 EGFR 突变型 II-IIIA 期（N1-N2）可切除 NSCLC（ADJUVANT/CTONG1104）的辅助治疗：一项随机、开放标签、III 期研究。
Lancet Oncol. 2018 Jan;19(1):139-148. doi: 10.1016/S1470-2045(17)30729-5. Epub 2017 Nov 21.
Zotero 插件